ANSWER: B

Rationale:

This question asked you to integrate the bilateral symmetric clinical presentation and normal DAT scan result to arrive at the correct diagnosis. Option B is correct. Drug-induced parkinsonism (DIP) characteristically presents with bilateral, symmetric motor features — bradykinesia and rigidity affecting both sides simultaneously — in contrast to idiopathic Parkinson's disease, which is almost invariably asymmetric at onset. The absence of resting tremor further supports DIP, as rest tremor is a hallmark of idiopathic PD but is frequently absent in the drug-induced form. The normal DAT scan is the critical discriminating finding: in DIP caused by D2 receptor antagonism, the nigrostriatal dopaminergic pathway is structurally intact — neurons have not been lost — so the dopamine transporter, which is expressed on presynaptic terminals, is present at normal density. The temporal correlation with risperidone initiation and the bilateral symmetric presentation together confirm the diagnosis of DIP.

• Option A: Option A is incorrect. Idiopathic PD presenting symmetrically would be atypical; moreover, a normal DAT scan in a patient with true idiopathic PD would be paradoxical rather than reassuring — the normal DAT scan here is consistent with DIP precisely because the neurons are intact from pharmacological blockade, not neurodegeneration.
• Option C: Option C is incorrect. Multiple system atrophy typically shows reduced DAT binding in the putamen, reflecting genuine nigrostriatal degeneration; a normal DAT scan argues against MSA with parkinsonian features.
• Option D: Option D is incorrect. Progressive supranuclear palsy also typically shows reduced DAT binding and additional features including vertical gaze palsy and axial rigidity that are not described here.
• Option E: Option E is incorrect. Vascular parkinsonism produces a gait disorder predominantly affecting the lower limbs with relatively preserved upper limb function, and the clinical picture here includes bilateral upper limb rigidity and bradykinesia, which is more consistent with drug-induced parkinsonism from a systemic dopamine receptor antagonist.

ANSWER: D

Rationale:

This question asked you to explain the pharmacological reason levodopa is ineffective in antipsychotic-induced drug-induced parkinsonism. Option D is correct. Risperidone is a high-affinity D2 receptor antagonist. In drug-induced parkinsonism, the motor deficit results from pharmacological blockade of postsynaptic D2 receptors in the striatum — the same receptors that dopamine must activate to support normal motor function. When levodopa is administered, it is absorbed, crosses the blood-brain barrier, and is decarboxylated to dopamine in the brain. However, that dopamine encounters D2 receptors that are occupied by risperidone. Because risperidone has high D2 receptor affinity, the endogenous dopamine produced from levodopa cannot compete effectively with the bound antipsychotic to displace it from the receptor. The receptor remains blocked, and the additional dopamine has no functional target at which to act in the striatum. This is why levodopa is generally ineffective in DIP caused by high-affinity D2 antagonists, and why the correct management strategy is substitution with a lower-D2-affinity antipsychotic rather than addition of levodopa.

• Option A: Option A is incorrect. While peripheral levodopa-to-dopamine conversion occurs (and is why carbidopa is co-administered), peripheral dopamine does not compete with risperidone at central D2 receptors and does not meaningfully affect risperidone's antipsychotic efficacy; this is not the mechanism of levodopa's ineffectiveness in DIP.
• Option B: Option B is incorrect. Risperidone does not induce CYP2D6 to degrade levodopa before absorption; levodopa is not significantly metabolized by CYP2D6, and its intestinal absorption is mediated by the LNAA transporter, not by CYP enzymes.
• Option C: Option C is incorrect. Risperidone does not destroy presynaptic dopaminergic terminals; D2 receptor blockade is pharmacologically reversible and does not cause excitotoxic neuronal death — the normal DAT scan in this patient confirms that presynaptic terminals are structurally intact.
• Option E: Option E is incorrect. Risperidone does not inhibit the large neutral amino acid transporter; it is a D2/5-HT2A receptor antagonist with no relevant pharmacological activity at LNAA transport proteins.

ANSWER: A

Rationale:

This question asked you to identify the most appropriate antipsychotic substitution for a patient with risperidone-induced DIP whose antipsychotic cannot be discontinued. Option A is correct. Quetiapine is an atypical antipsychotic that exerts its antipsychotic effects through a complex receptor profile including 5-HT2A, H1, and alpha-1 adrenergic antagonism, with relatively low D2 receptor affinity at the doses used for psychiatric indications. Its striatal D2 occupancy at clinical doses is substantially lower than that of risperidone, meaning that substituting quetiapine allows a greater proportion of striatal D2 receptors to be available for dopamine signaling — potentially permitting partial motor recovery while maintaining adequate control of psychotic symptoms. Quetiapine is the preferred first-line substitution in this clinical scenario because it avoids the complex mandatory monitoring requirements of clozapine.

• Option B: Option B is incorrect. Aripiprazole is not a full D2 agonist; it is a D2 partial agonist that can act as a functional antagonist in hyperdopaminergic states. Aripiprazole still has significant D2 receptor binding affinity and is associated with extrapyramidal adverse effects including akathisia; it is not the preferred substitution for a patient with established DIP who needs minimal striatal D2 blockade.
• Option C: Option C is incorrect. Haloperidol is a first-generation antipsychotic with very high D2 receptor affinity — among the highest of any antipsychotic — and is one of the agents most strongly associated with drug-induced parkinsonism. Reducing the haloperidol dose reduces antipsychotic efficacy without eliminating the D2 blockade responsible for motor adverse effects at clinically meaningful concentrations; this approach would worsen rather than improve the clinical situation.
• Option D: Option D is incorrect. Olanzapine does have D2 receptor blocking activity — it is not purely a 5-HT2A antagonist. While it has a more favorable D2/5-HT2A ratio than first-generation agents, olanzapine at full antipsychotic doses produces meaningful striatal D2 occupancy and is associated with drug-induced parkinsonism; this description of olanzapine's pharmacology is inaccurate.
• Option E: Option E is incorrect. Clozapine does have the lowest D2 receptor affinity and is an appropriate agent for DIP in psychiatric patients; however, it is not the appropriate first-line substitute because its mandatory blood count monitoring program — required due to the risk of agranulocytosis — represents a significant clinical management burden. Quetiapine is the preferred first-line choice precisely because it achieves low D2 affinity without the agranulocytosis risk and monitoring requirements of clozapine.

ANSWER: C

Rationale:

This question asked you to accurately characterize trihexyphenidyl's role and its key limitation in drug-induced parkinsonism. Option C is correct. In the striatal motor circuit, dopamine and acetylcholine exert reciprocally antagonistic modulatory effects: dopaminergic input suppresses cholinergic interneuron activity, and cholinergic activity modulates motor output. When D2 receptor blockade reduces dopaminergic signaling, the relative cholinergic tone increases, contributing to the motor features of DIP. Anticholinergic agents such as trihexyphenidyl and benztropine partially correct this imbalance by reducing muscarinic receptor activity, providing modest symptomatic relief — particularly for rigidity and tremor. However, central muscarinic receptor blockade in older patients with already-diminished cholinergic reserve produces cognitive impairment, confusion, and delirium that can be clinically severe. For this reason, anticholinergic agents in DIP are more appropriate for younger patients and carry significant limitations in patients over approximately 60 to 65 years of age. They represent a symptomatic interim measure, not a definitive treatment, and the antipsychotic substitution strategy is always the preferred approach when feasible.

• Option A: Option A is incorrect. Trihexyphenidyl does not reverse D2 receptor blockade; it does not interact with D2 receptors at all. Its mechanism is muscarinic receptor antagonism, and its effects are modest rather than reliable and complete. Its cognitive effects are clinically significant, particularly in older patients.
• Option B: Option B is incorrect. Anticholinergic agents do not worsen D2 receptor blockade; they act on a parallel pharmacological pathway through muscarinic receptors and do not interfere with risperidone's D2 binding or its consequences.
• Option D: Option D is incorrect. Trihexyphenidyl blocks muscarinic receptors on striatal cholinergic interneurons, not on dopaminergic terminals; reducing cholinergic interneuron activity partially compensates for the loss of dopaminergic suppression in DIP rather than worsening it.
• Option E: Option E is incorrect. Trihexyphenidyl does not displace antipsychotics from D2 receptors; it acts through an entirely different receptor system (muscarinic), provides only modest rather than complete relief, and its adverse effect profile makes it unsuitable as a universally preferred bridge therapy at any age.

ANSWER: E

Rationale:

This question asked you to identify the specific pharmacokinetic property of levodopa that makes perioperative withholding uniquely dangerous. Option E is correct. Levodopa's plasma half-life of approximately one hour is among the shortest of any medication used for a chronic neurological condition. Most oral medications held perioperatively have half-lives measured in hours to days, providing a substantial buffer between the last dose and the onset of clinically significant drug effect loss. Levodopa provides no such buffer: within two to three half-lives — two to three hours — plasma concentrations fall to pharmacologically inadequate levels. In a patient with advanced PD who depends on near-continuous dopaminergic support for any meaningful motor function, this produces progressive akinesia: loss of voluntary movement, inability to swallow, loss of airway protective reflexes, and profound rigidity. Aspiration pneumonia from dysphagia is a leading cause of death in advanced PD, and the perioperative setting concentrates this risk when antiparkinson medications are withheld. Standard NPO-and-hold protocols are appropriate for most medications but fail to account for levodopa's uniquely short half-life and the uniquely severe consequences of dopaminergic withdrawal in advanced PD.

• Option A: Option A is incorrect. Levodopa undergoes first-order elimination, not zero-order; its plasma concentration decline follows predictable exponential kinetics that make its short half-life clinically calculable and the urgency of replacement planning clear.
• Option B: Option B is incorrect. Levodopa is minimally protein-bound — approximately 10 to 30% — and fasting-related changes in albumin do not meaningfully alter its free fraction in a way relevant to perioperative CNS delivery.
• Option C: Option C is incorrect. While levodopa does undergo some peripheral decarboxylation, carbidopa co-administration substantially inhibits this process; fasting does not meaningfully increase first-pass extraction, and this is not the pharmacokinetic basis for the perioperative danger of withholding levodopa.
• Option D: Option D is incorrect. Levodopa does not have a large volume of distribution; its CNS entry is governed by active LNAA transporter-mediated uptake rather than passive redistribution from a large peripheral compartment, and perioperative fluid shifts do not cause redistribution of levodopa out of the brain in the manner described.

ANSWER: B

Rationale:

This question asked you to identify the established perioperative dopaminergic bridging strategy for a patient who cannot take oral medications. Option B is correct. Rotigotine is a dopamine agonist formulated as a transdermal patch that delivers continuous, stable drug absorption through the skin, completely bypassing the requirement for oral intake or gastrointestinal function. It can be applied before surgery begins and maintained through the fasting period, providing basal dopaminergic tone that prevents the acute akinesia and aspiration risk associated with levodopa withdrawal. Rotigotine transdermal is the established and most widely applicable perioperative bridging strategy for PD patients who cannot take oral medications.

• Option A: Option A is incorrect. Levodopa/carbidopa is not available as an intravenous formulation; there is no IV levodopa product approved or widely available for clinical use in perioperative settings. The absence of an IV formulation is precisely why alternative bridging strategies are required.
• Option C: Option C is incorrect. Nasogastric tube placement for levodopa administration is logistically complex, requires an additional procedure with its own aspiration risk in a patient with already-compromised airway protection, and is not the standard approach when transdermal rotigotine is available as a simpler and safer alternative. Gut motility may also be impaired in the perioperative period, reducing the reliability of nasogastric levodopa delivery.
• Option D: Option D is incorrect. Subcutaneous apomorphine infusion is a legitimate advanced therapy for motor fluctuations in PD and can be used perioperatively; however, it requires specialist initiation, titration experience, and a pump delivery system that is not routinely available in general surgical settings. Rotigotine transdermal is the more broadly accessible standard perioperative bridging approach.
• Option E: Option E is incorrect. Levodopa does not have an extended tissue distribution that sustains therapeutic plasma levels for 24 hours after a single dose; its plasma half-life of approximately one hour means that plasma concentrations fall within hours of the last dose regardless of the dose size. Doubling or tripling the single dose does not meaningfully extend the duration of therapeutic effect.

ANSWER: D

Rationale:

This question asked you to identify the appropriate antiemetic substitute and explain precisely why metoclopramide is contraindicated in Parkinson's disease. Option D is correct. Metoclopramide is a dopamine D2 receptor antagonist that readily crosses the blood-brain barrier. When administered to a patient with Parkinson's disease, it blocks the same striatal D2 receptors that dopaminergic therapy is working to activate, directly worsening parkinsonism — increasing rigidity, bradykinesia, and dysphagia. This effect is dose-independent: even standard antiemetic doses produce clinically meaningful striatal D2 blockade in PD patients. There is no safe dose of metoclopramide in Parkinson's disease, and it is explicitly contraindicated. Ondansetron is a selective serotonin 5-HT3 receptor antagonist with no affinity for dopamine receptors at any clinically relevant concentration. It provides effective antiemetic coverage for postoperative nausea without any mechanism capable of worsening parkinsonism and is the established first-choice antiemetic in PD.

• Option A: Option A is incorrect. Prochlorperazine is a phenothiazine antipsychotic with potent D2 receptor blocking activity — it is contraindicated in Parkinson's disease for the same reason as metoclopramide and haloperidol. It does not have weaker D2 affinity in a way that makes it safe in PD; phenothiazines as a class carry significant parkinsonian adverse effect risk.
• Option B: Option B is incorrect. Domperidone is pharmacologically accurate — it is a peripheral D2 antagonist with limited CNS penetration that is used as a PD-safe antiemetic in countries where it is available. However, domperidone is not approved or available in the United States, making it an impractical answer in a clinical US context; ondansetron is the established US standard of care for antiemesis in PD.
• Option C: Option C is incorrect. Metoclopramide's contraindication in PD is not because it increases peripheral dopamine levels affecting levodopa absorption; it is because it blocks CNS D2 receptors directly. Lorazepam is not a standard first-line antiemetic and carries significant sedation, respiratory, and fall risks in older patients with PD.
• Option E: Option E is incorrect. Haloperidol is a first-generation antipsychotic with very high D2 receptor affinity and is one of the most potent inducers of drug-induced parkinsonism available; it is absolutely contraindicated in Parkinson's disease, and the claim that low antiemetic doses produce less striatal D2 occupancy than metoclopramide in a way that makes it safer in PD is pharmacologically incorrect.

ANSWER: A

Rationale:

This question asked you to identify the appropriate pharmacological management of postoperative delirium in a patient with Parkinson's disease and explain why haloperidol must be avoided. Option A is correct across all components. Quetiapine at 12.5 to 25 mg has very low D2 receptor affinity at these doses for psychiatric and behavioral indications, making it the preferred pharmacological agent when treatment of agitation or delirium in PD is necessary. Equally important is the clinical recognition that inadequate dopaminergic therapy — levodopa withdrawal or insufficient rotigotine coverage — can itself cause or worsen postoperative confusion, agitation, and rigidity in PD patients; confirming that antiparkinson medications are in place and adequate is a first-line non-pharmacological intervention. Haloperidol must not be used: it is a high-affinity D2 receptor antagonist that will severely worsen motor function, increasing rigidity to a degree that may produce aspiration, and worsening the very agitation it is intended to treat through drug-induced motor distress.

• Option B: Option B is incorrect. There is no safe dose of haloperidol in Parkinson's disease; the claim that 0.5 mg IV produces sub-threshold D2 occupancy for extrapyramidal adverse effects in PD patients is not supported by clinical pharmacology or practice guidelines. Even low haloperidol doses cause clinically significant worsening of motor function in PD.
• Option C: Option C is incorrect. While lorazepam has no dopaminergic activity, it carries significant risks in older PD patients — paradoxical agitation, excessive sedation, respiratory depression, and aspiration risk — and is not the preferred first-line pharmacological agent for delirium management. Avoiding all antipsychotic agents in PD delirium is overstated; quetiapine and pimavanserin are both appropriate options.
• Option D: Option D is incorrect. Risperidone has significant D2 receptor affinity even at low doses and is one of the antipsychotics most commonly associated with drug-induced parkinsonism; it is not a safe low-dose option in PD and would worsen rather than improve the motor situation.
• Option E: Option E is incorrect. Pimavanserin is appropriate for PD psychosis and is an option for PD delirium, but describing it as universally safe in any dose for acute agitation management regardless of acuity is misleading; pimavanserin has a slow onset of action and is not established as a rapid-acting agent for acute behavioral emergencies in the ICU setting. Quetiapine is the more clinically validated choice for acute postoperative behavioral management in PD.

ANSWER: C

Rationale:

This question asked you to identify which antiparkinson agent has the most human pregnancy experience and is generally continued when treatment is required during pregnancy. Option C is correct. Levodopa has been used during pregnancy since the earliest days of its clinical application and has accumulated the largest body of human pregnancy outcome data of any antiparkinson drug. While animal studies at high doses have shown skeletal malformations, human case series at therapeutic doses have not demonstrated a consistent teratogenic signal. The co-administration of carbidopa is pharmacologically beneficial during pregnancy: carbidopa inhibits peripheral AADC but does not cross the blood-brain barrier, meaning it limits peripheral levodopa-to-dopamine conversion (reducing nausea and cardiovascular effects) without affecting fetal CNS dopamine levels directly. When motor symptoms are significant enough to impair safe functioning during pregnancy — including the risk of falls and aspiration — levodopa/carbidopa at the lowest effective dose is the preferred and best-supported pharmacological option.

• Option A: Option A is incorrect. Non-ergot dopamine agonists including ropinirole have very limited human pregnancy data; their classification is based on preclinical toxicology findings, and they do not have a favorable or established first-trimester safety record compared to levodopa. A more favorable placental transfer profile has not been demonstrated for ropinirole compared to levodopa.
• Option B: Option B is incorrect. Rasagiline has essentially no human pregnancy safety data, and the theoretical neuroprotective rationale does not justify first-trimester exposure given the unknown fetal effects of MAO-B inhibition on monoamine neurotransmitter development; rasagiline should be discontinued in pregnancy.
• Option D: Option D is incorrect. Continuing all three agents unchanged ignores the meaningful differences in pregnancy safety profiles between the agents; ropinirole and rasagiline should be discontinued given their limited safety data, while levodopa is continued.
• Option E: Option E is incorrect. Amantadine is not the antiparkinson agent with the best human pregnancy safety record; it is generally also discontinued during pregnancy due to lack of safety data and theoretical risks. Levodopa, not amantadine, is the agent with the most pregnancy experience and the one most generally supported for continuation when clinically necessary.

ANSWER: E

Rationale:

This question asked you to identify the correct explanation for why ropinirole is generally discontinued during the first trimester. Option E is correct. Ropinirole is used predominantly in older PD populations and in restless legs syndrome; its exposure in women of reproductive age is limited, and human pregnancy outcome data is correspondingly sparse. Unlike levodopa, which has accumulated decades of human pregnancy experience through its continuous use in PD since the 1970s, ropinirole's safety classification during pregnancy rests primarily on preclinical animal toxicology studies. During the first trimester — when organogenesis is occurring and teratogenic risk is highest — the appropriate risk-minimizing approach in the absence of well-characterized human safety data is discontinuation of the agent when a better-characterized alternative (levodopa) is available and effective. This is a precautionary decision based on evidence absence rather than evidence of harm; there is no confirmed human teratogenic signal for ropinirole, but the absence of safety data during organogenesis is itself the clinical rationale for discontinuation.

• Option A: Option A is incorrect. Permanent fetal striatal D2 receptor downregulation from ropinirole exposure has not been established as a mechanism or clinical outcome in human pregnancy; this represents speculation beyond the available evidence, and it is not the established rationale for ropinirole discontinuation.
• Option B: Option B is incorrect. While CYP1A2 activity does increase during pregnancy, this does not make therapeutic ropinirole concentrations unachievable; dose adjustment could theoretically maintain therapeutic levels, and pharmacokinetic changes are not the clinical rationale for discontinuing ropinirole in the first trimester.
• Option C: Option C is incorrect. While ropinirole does suppress prolactin through D2 receptor agonism, this suppression does not interfere with the progesterone-dependent corpus luteum maintenance during early pregnancy in the way described; this is not an established mechanism of pregnancy risk for dopamine agonists and is not the clinical rationale for discontinuation.
• Option D: Option D is incorrect. There are no randomized controlled trials of ropinirole in pregnant PD patients, and no definitive human teratogenic signal has been established for ropinirole; the decision to discontinue is based on absence of safety data rather than confirmed evidence of neural tube defects or other specific malformations.

ANSWER: B

Rationale:

This question asked you to correctly address the patient's question about rasagiline's relative safety in pregnancy and the neuroprotective argument. Option B is correct. Rasagiline has essentially no human pregnancy safety data — its use in women of reproductive age is uncommon, and no meaningful case series or prospective studies exist to characterize its fetal safety profile. This absence of safety data is itself the primary clinical rationale for discontinuation. Additionally, MAO-B inhibition has theoretical developmental implications: monoamine oxidase enzymes participate in the regulation of serotonin, dopamine, and norepinephrine metabolism throughout the developing central and peripheral nervous system. Inhibiting MAO-B during organogenesis and fetal nervous system development carries uncharacterized theoretical risks. Regarding the neuroprotective argument: while rasagiline has been studied for potential neuroprotective effects in clinical trials, no established benefit has been confirmed that would justify exposing a developing fetus to a drug with no pregnancy safety data. The neuroprotective rationale does not override the precautionary principle when an alternative (levodopa) is available.

• Option A: Option A is incorrect. Rasagiline does cross the blood-brain barrier to exert its CNS effects and likely crosses the placenta; the assertion that MAO-B inhibitors are confined to the maternal peripheral nervous system and do not reach the fetus is pharmacologically inaccurate and not the basis for any clinical guidance.
• Option C: Option C is incorrect. Dose reduction is not an evidence-based strategy for managing rasagiline in pregnancy; the issue is the complete absence of safety data at any dose, and the neuroprotective dose distinction does not resolve the fetal safety concern.
• Option D: Option D is incorrect. While rasagiline does produce irreversible MAO-B inhibition, this does not mean the drug itself is absent from fetal circulation; the drug must be absorbed, distributed, and metabolized before its effects are established, and fetal exposure occurs during this process regardless of the mechanism of enzyme inhibition. The irreversibility of MAO-B inhibition is a pharmacodynamic property, not a pharmacokinetic property that eliminates fetal drug exposure.
• Option E: Option E is incorrect. No clinical studies in pregnant women with Parkinson's disease have established rasagiline's first-trimester safety; this statement is factually false. The absence of such studies is the clinical problem, not the basis for reassurance.

ANSWER: D

Rationale:

This question asked you to identify the correct mechanism by which dopamine agonists affect lactation and the clinical implication for a patient wishing to breastfeed. Option D is correct. Prolactin secretion from the anterior pituitary is under tonic inhibitory control by dopamine acting at D2 receptors on lactotroph cells. Dopamine agonists mimic this inhibitory signal, suppressing prolactin release from the pituitary. Because prolactin is the primary hormonal driver of milk synthesis in the mammary alveolar cells, reduced prolactin leads directly to reduced milk production — and at therapeutic dopamine agonist doses used for Parkinson's disease, suppression may be severe enough to make breastfeeding impossible or impractical. This mechanism is so pharmacologically reliable that bromocriptine, an ergot dopamine agonist, was historically used therapeutically to suppress lactation. For this patient, reintroducing a dopamine agonist while attempting to breastfeed creates a direct pharmacological conflict, and an explicit shared decision-making conversation is required: she may need to choose between dopamine agonist therapy and breastfeeding.

• Option A: Option A is incorrect. Dopamine agonists do not suppress oxytocin release as their primary mechanism of lactation interference; oxytocin mediates the milk let-down reflex, which is a distinct physiological process from milk synthesis. The primary effect of dopamine agonists on lactation is through prolactin suppression and reduced milk production, not impaired milk ejection.
• Option B: Option B is incorrect. Dopamine agonists do not compete with prolactin for receptor binding at the mammary gland level; their effect is entirely upstream at the pituitary, reducing prolactin secretion rather than blocking its peripheral action. Increased suckling frequency cannot overcome pharmacologically suppressed prolactin production.
• Option C: Option C is incorrect. Dopamine agonists do not block beta-adrenergic receptors in mammary epithelial cells; this mechanism does not describe the pharmacology of dopamine agonists. Their mechanism of lactation suppression is entirely through D2 receptor-mediated prolactin inhibition at the anterior pituitary.
• Option E: Option E is incorrect. While dopamine agonists can cause nausea and appetite reduction as adverse effects, the mechanism of lactation suppression is direct and pharmacological through prolactin inhibition — it is not mediated by maternal nutritional status, and caloric supplementation cannot overcome the hormonal prolactin deficit caused by dopamine agonist therapy.

ANSWER: A

Rationale:

This question asked you to identify the appropriate initial antiparkinson monotherapy in an older adult and explain the pharmacological rationale. Option A is correct. Current movement disorder guidelines recommend initiating antiparkinson therapy with levodopa/carbidopa rather than a dopamine agonist in patients over 70 years of age. This recommendation is driven by the substantially elevated adverse effect risk profile of dopamine agonists in older patients. Age-related changes in autonomic reflexes increase orthostatic hypotension risk; reduced cholinergic reserve amplifies hallucination and cognitive impairment risk; altered sleep architecture exacerbates excessive daytime sleepiness; and the detection of impulse control disorders is complicated by cognitive changes. Levodopa provides reliable and well-tolerated motor efficacy without these class-specific risks. Additionally, pramipexole is approximately 90% renally eliminated and requires dose adjustment in patients with eGFR below 50 mL/min — this patient's eGFR of 42 mL/min makes pramipexole prescribing more complex and increases toxicity risk.

• Option B: Option B is incorrect. The motor fluctuation and dyskinesia delay observed with dopamine agonists in younger patients does not apply equally to older adults; moreover, the adverse effect burden of dopamine agonists in this age group typically outweighs the motor fluctuation delay benefit, which is why guidelines recommend levodopa first in patients over 70.
• Option C: Option C is incorrect. There is no black-box warning for levodopa/carbidopa related to neuroleptic malignant syndrome at doses above 200 mg in older adults; this is a fabricated limitation. Levodopa dose is titrated to motor response with monitoring for standard dopaminergic adverse effects, not based on an age-specific dose cap.
• Option D: Option D is incorrect. Older patients do not have reduced hepatic COMT activity in a way that causes clinically significant levodopa accumulation at standard doses; COMT activity is not a rate-limiting factor in levodopa pharmacokinetics that requires routine therapeutic drug monitoring.
• Option E: Option E is incorrect. Age-related pharmacodynamic differences between levodopa and dopamine agonists are clinically significant and do influence agent selection; the guideline recommendation for levodopa-first in patients over 70 is explicitly based on these differences.

ANSWER: C

Rationale:

This question asked you to accurately characterize pramipexole's renal dose adjustment requirement and explain the pharmacokinetic basis. Option C is correct. Pramipexole is primarily eliminated by the kidneys, with approximately 90% of an administered dose excreted unchanged in the urine via active renal tubular secretion. This high renal excretion fraction means that renal clearance is the dominant pharmacokinetic pathway for pramipexole elimination. When eGFR falls substantially — as in this patient with an eGFR of 28 mL/min — renal clearance of pramipexole is markedly reduced, and the drug accumulates in plasma. Elevated pramipexole exposure increases the risk and severity of its dose-dependent adverse effects: excessive daytime sleepiness, orthostatic hypotension, hallucinations, nausea, and impulse control disorders. Prescribing information for pramipexole provides specific dose reduction guidance based on eGFR thresholds, and this patient's eGFR of 28 mL/min places her in a category requiring meaningful dose reduction. Rotigotine transdermal, whose pharmacokinetics are not substantially affected by renal impairment, may be a preferable dopamine agonist in this setting.

• Option A: Option A is incorrect. Pramipexole does not undergo extensive hepatic glucuronidation as a primary elimination pathway; approximately 90% of the dose is excreted unchanged by the kidney, not as a metabolite. The pharmacokinetic profile is predominantly renal, not hepatic.
• Option B: Option B is incorrect. While pharmacodynamic sensitivity in older adults is a real consideration, pramipexole's renal dose adjustment requirement is a pharmacokinetic concern — drug accumulation from reduced renal clearance — not purely a pharmacodynamic age-related sensitivity issue. Ignoring renal function in dose selection for pramipexole is not appropriate at an eGFR of 28 mL/min.
• Option D: Option D is incorrect. Pramipexole does not have an established active metabolite (N-despropyl-pramipexole) that accumulates to clinically relevant concentrations in renal impairment; the parent compound's own accumulation from impaired renal tubular secretion is the pharmacokinetic concern.
• Option E: Option E is incorrect. Pramipexole dose adjustment is required at eGFR levels well above 15 mL/min; prescribing information specifies dose adjustments beginning at eGFR thresholds of approximately 30 to 50 mL/min depending on the specific dosing schedule. An eGFR of 28 mL/min clearly requires adjustment, not standard dosing with quarterly monitoring.

ANSWER: E

Rationale:

This question asked you to identify the pharmacodynamic mechanism responsible for clinical deterioration in an older PD patient on multiple anticholinergic agents. Option E is correct. Both oxybutynin and diphenhydramine exert significant central muscarinic receptor blocking (anticholinergic) activity. Oxybutynin crosses the blood-brain barrier and has well-documented central anticholinergic effects; diphenhydramine is a first-generation antihistamine with potent central muscarinic antagonism, making it one of the most cognitively harmful agents in the Beers Criteria for older adults. In an 81-year-old patient with Parkinson's disease — in whom cholinergic neurotransmission is already reduced as part of the neurodegenerative process — the additional muscarinic receptor blockade from two peripherally prescribed agents produces a cumulative anticholinergic burden that impairs cognitive processing speed, working memory, and attentional vigilance. Slowed reaction time, impaired gait stability, and reduced fall-avoidance reflexes all contribute to the fall risk. This mechanism operates independently of and additively with any effects of the levodopa regimen itself. A structured medication review targeting anticholinergic burden — with discontinuation of diphenhydramine as the highest-priority step, followed by switching oxybutynin to a bladder-selective agent such as mirabegron — is the appropriate intervention.

• Option A: Option A is incorrect. Oxybutynin and diphenhydramine do not produce serotonergic excess; their receptor pharmacology is muscarinic antagonism and histamine H1 antagonism respectively, not serotonergic activity. The clinical presentation is anticholinergic toxicity, not serotonin syndrome.
• Option B: Option B is incorrect. Oxybutynin and diphenhydramine do not meaningfully inhibit CYP3A4 and CYP2D6 respectively in a way that produces clinically significant levodopa accumulation; levodopa's primary metabolic pathways are through AADC and COMT, not through CYP2D6 or CYP3A4.
• Option C: Option C is incorrect. While orthostatic hypotension does contribute to falls in PD, oxybutynin and diphenhydramine are not peripheral vasodilators; they are anticholinergic agents. Peripheral vasodilation is not their pharmacological mechanism, and pure orthostatic hypotension would not explain the cognitive fogginess and daytime confusion described.
• Option D: Option D is incorrect. While anticholinergic agents do reduce gut motility and can delay gastric emptying, this effect on levodopa absorption would not account for the persistent daytime cognitive fogginess described; the central anticholinergic mechanism — direct CNS muscarinic receptor blockade — is the primary driver of the cognitive and fall-related deterioration in this patient.

ANSWER: B

Rationale:

This question asked you to recommend the correct dietary modification and explain the pharmacokinetic mechanism of meal-related levodopa wearing-off. Option B is correct. Levodopa depends on the large neutral amino acid (LNAA) transporter — specifically the LAT1 isoform — for absorption across the intestinal epithelium into the systemic circulation and for transport across the blood-brain barrier into the CNS. Both of these transport steps are competitively inhibited by dietary amino acids released during protein digestion. After a protein-rich midday meal, the plasma concentration of large neutral amino acids rises substantially, competing with levodopa at both transport sites and producing the characteristic post-meal motor wearing-off. The protein redistribution diet addresses this by concentrating the day's protein in the evening meal — when motor demands are typically lower and consistent levodopa efficacy is less critical — while keeping breakfast and lunch low in protein. This removes the competitive amino acid load from both the intestinal and blood-brain barrier transport sites during the active daytime period.

• Option A: Option A is incorrect. The distinction between animal and plant protein in terms of LNAA content is not the relevant clinical variable; both sources contribute phenylalanine, tyrosine, leucine, and other large neutral amino acids that compete at the transporter. Eliminating all animal protein permanently is nutritionally extreme and unnecessary; the protein redistribution strategy achieves the goal while preserving dietary adequacy and flexibility.
• Option C: Option C is incorrect. Protein does not buffer gastric acid in a way that improves levodopa tablet dissolution; taking levodopa with protein-rich food directly worsens the LNAA competition problem by maximizing amino acid load at exactly the time of drug administration. The pH-dissolution mechanism is not the primary explanation for protein-related wearing-off.
• Option D: Option D is incorrect. Increasing the levodopa dose empirically to overwhelm transporter competition risks dose-dependent dyskinesia and adverse effects without reliably overcoming a competitive saturable transport mechanism; the protein redistribution dietary approach addresses the competitive load itself rather than attempting to saturate the transporter with drug.
• Option E: Option E is incorrect. Entacapone inhibits peripheral COMT-mediated levodopa degradation, extending plasma levodopa half-life — a useful adjunct for wearing-off in general. However, COMT inhibition does not address LNAA transporter competition, which occurs upstream of the degradation step. Protein does not reduce levodopa plasma half-life through COMT induction; the mechanism is competitive transport, not accelerated degradation.

ANSWER: D

Rationale:

This question asked you to identify the precise pharmacodynamic mechanism of the meperidine-rasagiline interaction producing this clinical emergency. Option D is correct. Meperidine is pharmacologically unique among commonly used opioid analgesics in possessing serotonin reuptake inhibiting activity in addition to its mu-opioid receptor agonist properties. When serotonin reuptake is blocked, synaptic serotonin concentrations rise. Simultaneously, rasagiline inhibits MAO-B, an enzyme that participates in the oxidative deamination and inactivation of serotonin; with MAO-B inhibited, serotonin that escapes reuptake is catabolized more slowly, further amplifying the synaptic accumulation. The combination of impaired serotonin reuptake and impaired serotonin catabolism elevates synaptic serotonin to levels that produce serotonin syndrome — characterized by the diagnostic triad of neuromuscular abnormalities (rigidity, clonus, hyperreflexia, myoclonus), autonomic instability (hyperthermia, tachycardia, diaphoresis), and altered mental status (agitation, confusion). This interaction is among the most dangerous drug combinations in the antiparkinson pharmacological armamentarium and is an absolute contraindication listed in rasagiline prescribing information.

• Option A: Option A is incorrect. Meperidine does have some anticholinergic properties, but central anticholinergic toxidrome does not produce hyperthermia, severe rigidity, and tachycardia of this severity or time course; rasagiline does not inhibit acetylcholinesterase, and this is not the mechanism of the interaction.
• Option B: Option B is incorrect. Meperidine is not transported by the LNAA transporter and does not compete with levodopa at this site; opioids are not substrates of the LNAA transport system, and this mechanism does not describe any established drug interaction.
• Option C: Option C is incorrect. Meperidine's analgesic activity is primarily through mu-opioid receptors, not kappa receptors; kappa-opioid receptor pharmacology is not the basis for this interaction, and rasagiline does not inhibit kappa-opioid receptor catabolism through any established pathway.
• Option E: Option E is incorrect. Normeperidine toxicity is a recognized adverse effect of meperidine in patients with renal impairment, where normeperidine accumulates and produces excitatory CNS effects including seizures. However, normeperidine is metabolized primarily by hepatic pathways rather than by MAO-B, and the time course of normeperidine accumulation is hours to days, not fifteen minutes. The acute onset of the full serotonergic triad fifteen minutes after meperidine administration is the hallmark of serotonin syndrome, not normeperidine toxicity.

ANSWER: A

Rationale:

This question asked you to identify safe opioid alternatives for a patient on rasagiline following serotonin syndrome from meperidine. Option A is correct. Morphine and oxycodone are standard mu-opioid receptor agonists that achieve analgesia through their interaction with opioid receptors without meaningful serotonin reuptake inhibiting activity at clinical doses. Because serotonin reuptake inhibition is the specific property of meperidine that produces the dangerous pharmacodynamic interaction with MAO-B inhibitors — by raising synaptic serotonin in the setting of impaired serotonin catabolism — opioids without this serotonergic property do not carry the same risk. Morphine and oxycodone are the established safe opioid alternatives in patients on MAO inhibitors, and their use is supported by clinical experience and pharmacological reasoning. Fentanyl is also generally considered safe and is another reasonable option.

• Option B: Option B is incorrect. Tramadol is explicitly contraindicated in patients on MAO inhibitors, including the selective MAO-B inhibitors used in PD such as rasagiline and selegiline. Tramadol is both a mu-opioid agonist and a serotonin-norepinephrine reuptake inhibitor; its serotonergic activity is clinically significant and sufficient to produce serotonin syndrome when combined with MAO-B inhibitors. The claim that its lower serotonin transporter affinity makes it safe is incorrect and potentially dangerous.
• Option C: Option C is incorrect. Codeine is a prodrug that requires CYP2D6-mediated hepatic conversion to morphine for analgesic activity; the prodrug itself does have opioid receptor activity through its partial conversion. More importantly, codeine's interaction profile with MAO inhibitors is not characterized by the prodrug/active drug distinction — the safety concern for any opioid with MAO inhibitors relates to its serotonergic properties rather than its prodrug status.
• Option D: Option D is incorrect. Tapentadol is a dual mu-opioid agonist and norepinephrine reuptake inhibitor; while it has less serotonin reuptake inhibiting activity than tramadol, it is generally considered potentially risky in combination with MAO inhibitors given its monoamine reuptake inhibiting properties. It is not the established safe choice when morphine and oxycodone are available.
• Option E: Option E is incorrect. Fentanyl is generally considered a safe opioid alternative with MAO-B inhibitors and is a reasonable choice; however, the statement that it is the only opioid with pharmacological certainty of safety is overstated and inaccurate. Morphine and oxycodone are equally established as safe alternatives, and restricting the clinician to fentanyl alone is not supported by the pharmacological evidence.

ANSWER: C

Rationale:

This question asked you to identify the specific concern with ketamine in patients on dopaminergic antiparkinson therapy. Option C is correct. Ketamine produces sympathomimetic effects through stimulation of catecholamine release from sympathetic nerve terminals, the adrenal medulla, and central sympathetic pathways, resulting in tachycardia, hypertension, and increased cardiac output. In a patient with Parkinson's disease on dopaminergic therapy — where central and peripheral catecholaminergic tone may be sensitized or elevated — these sympathomimetic effects can be amplified, increasing the risk of hemodynamic instability during induction or supplemental use. This is a caution rather than an absolute contraindication: ketamine can be used in PD patients when clinically indicated, but it requires appropriate cardiovascular monitoring and awareness of the potential for exaggerated sympathomimetic responses. Regional anesthesia is generally preferred in PD when surgically feasible specifically to avoid the interaction landscape of systemic anesthetic agents.

• Option A: Option A is incorrect. Ketamine is not a COMT inhibitor and does not compete with entacapone at the COMT enzyme; its pharmacology is NMDA receptor antagonism and sympathomimetic catecholamine release, not COMT inhibition.
• Option B: Option B is incorrect. Ketamine is metabolized primarily by hepatic CYP3A4 and CYP2B6, not by MAO-B; rasagiline's MAO-B inhibition does not meaningfully affect ketamine pharmacokinetics, and ketamine accumulation from MAO-B inhibition is not an established interaction.
• Option D: Option D is incorrect. While both ketamine and amantadine act at NMDA receptors, ketamine's anesthetic use does not directly reverse amantadine's therapeutic antiparkinson effects in a clinically meaningful way during a surgical procedure; competitive NMDA pharmacodynamic antagonism between these two agents is not an established or clinically significant concern that constitutes a contraindication.
• Option E: Option E is incorrect. Using ketamine to compensate for levodopa-related orthostatic hypotension would be pharmacologically imprudent; the sympathomimetic amplification concern in the dopaminergic state makes ketamine a less suitable hemodynamic rescue agent in PD rather than a preferred one, and its risks outweigh any incidental hemodynamic benefit.

ANSWER: E

Rationale:

This question asked you to identify the pharmacokinetic drug interaction between ciprofloxacin and rasagiline and recommend the correct antibiotic alternative. Option E is correct. Rasagiline undergoes primary hepatic metabolism through CYP1A2-mediated N-dealkylation to aminoindan. Ciprofloxacin is a potent inhibitor of CYP1A2 — one of the most significant clinical CYP1A2 inhibitors in common use. When ciprofloxacin inhibits CYP1A2, rasagiline's hepatic clearance is substantially reduced, leading to marked elevation of plasma rasagiline concentrations. At elevated concentrations, rasagiline's MAO-B inhibitory burden increases, proportionally raising the risk of its known dangerous pharmacodynamic interactions — particularly serotonin syndrome risk from any concurrently administered serotonergic agent and hypertensive reactions from sympathomimetic agents. This interaction is documented in rasagiline's prescribing information, which specifically identifies ciprofloxacin as an agent to avoid or use with extreme caution. Given that this patient's infection is sensitive to trimethoprim-sulfamethoxazole and nitrofurantoin — neither of which is a clinically meaningful CYP1A2 inhibitor — the correct clinical decision is straightforward: use one of the available safe alternatives.

• Option A: Option A is incorrect. Ciprofloxacin does have clinically significant mammalian enzyme targets beyond its antibacterial mechanism; its CYP1A2 inhibitory activity is well established and represents a real pharmacokinetic interaction with rasagiline, not a theoretical concern.
• Option B: Option B is incorrect. While the serotonin syndrome risk from rasagiline is specifically pharmacodynamic through serotonergic agents, the ciprofloxacin-rasagiline concern is pharmacokinetic — CYP1A2 inhibition elevating rasagiline levels — and is entirely separate from and independent of ciprofloxacin having serotonergic properties. Elevated rasagiline levels increase all of rasagiline's drug interaction risks regardless of the class of the interacting agent.
• Option C: Option C is incorrect. Rasagiline produces irreversible MAO-B inhibition; the enzyme does not recover within 24 hours of cessation. New MAO-B enzyme synthesis takes approximately two weeks for full activity recovery. Temporarily discontinuing rasagiline would not protect against the pharmacokinetic interaction during the antibiotic course and would leave the patient without antiparkinson MAO-B inhibitor coverage unnecessarily when a safe antibiotic alternative exists.
• Option D: Option D is incorrect. Reducing the ciprofloxacin dose does not reliably attenuate its CYP1A2 inhibitory effect to a safe level in a predictable or validated manner; CYP1A2 inhibition by ciprofloxacin occurs at concentrations achieved throughout the standard dosing range. When safe alternatives are available, avoiding the interacting agent entirely is always preferable to attempting empiric dose adjustment of the inhibitor.

ANSWER: B

Rationale:

This question asked you to identify the correct diagnosis and mechanism based on the medication history and DAT scan result. Option B is correct. The clinical history — bilateral symmetric parkinsonism developing after years of valproic acid therapy in a patient with no exposure to D2-blocking antipsychotics or antiemetics — combined with a normal DAT scan, is characteristic of valproic acid-induced parkinsonism. Valproic acid causes parkinsonism through a mechanism distinct from antipsychotic D2 receptor blockade: it impairs mitochondrial oxidative phosphorylation and energy metabolism in dopaminergic neurons, reducing their capacity for dopamine synthesis and neurotransmission. This functional metabolic impairment produces the clinical features of parkinsonism without causing the structural loss of presynaptic dopaminergic terminals that would reduce DAT binding. The normal DAT scan is therefore the expected and diagnostically informative finding — it confirms that the nigrostriatal pathway is structurally intact, pointing away from idiopathic PD and toward a drug-induced functional mechanism.

• Option A: Option A is incorrect. In idiopathic PD, even early pre-motor cases typically show reduced DAT binding in the putamen on sensitive imaging; a completely normal bilateral DAT scan in a patient with established motor parkinsonism argues strongly against idiopathic PD as the primary diagnosis.
• Option C: Option C is incorrect. Valproic acid does not block D2 receptors; D2 receptor antagonism is the mechanism of antipsychotic-induced DIP. Valproate's mechanism is mitochondrial dysfunction at the presynaptic neuronal level, not postsynaptic receptor blockade.
• Option D: Option D is incorrect. While lithium can rarely cause parkinsonism, the patient's history specifies valproic acid as the long-term mood stabilizer; introducing lithium as an unconfirmed variable without basis in the clinical history is speculative and not the most parsimonious explanation.
• Option E: Option E is incorrect. A DAT scan is not used to diagnose psychogenic parkinsonism, and a normal DAT scan does not itself confirm a functional disorder; a normal DAT scan is the expected finding in multiple drug-induced and structural causes of parkinsonism where presynaptic terminals are intact, and valproic acid-induced parkinsonism is the most pharmacologically coherent explanation given the medication history.

ANSWER: D

Rationale:

This question asked you to respond correctly to a significant ALT elevation in a patient on tolcapone. Option D is correct. Tolcapone carries a black-box warning for potentially fatal hepatotoxicity, including fulminant hepatic failure resulting in death. The mandatory monitoring program — baseline liver function tests followed by periodic testing at defined intervals during therapy — exists specifically to detect early hepatotoxicity before it progresses to irreversible hepatic injury or failure. An ALT elevation of 4.1 times the upper limit of normal at eight weeks in a patient with a previously normal baseline is a clinically significant hepatotoxicity signal that mandates immediate drug discontinuation. The fact that the patient is asymptomatic does not make this finding benign — fulminant hepatic failure can develop rapidly from a point of asymptomatic enzyme elevation, and the purpose of monitoring is to act before symptoms appear. Hepatology review is appropriate given the magnitude of the elevation, and the patient must be counseled on symptoms of hepatic decompensation to watch for after discontinuation. Alternative wearing-off strategies — entacapone, MAO-B inhibitor addition, or levodopa dose interval adjustment — should be discussed.

• Option A: Option A is incorrect. Monitoring with continued drug exposure is not the recommended response to a significant ALT elevation on tolcapone; the prescribing information and black-box warning mandate discontinuation upon significant liver enzyme elevation, not intensified monitoring of an ongoing exposure.
• Option B: Option B is incorrect. Dose reduction is not an evidence-based management strategy for tolcapone-induced hepatotoxicity; the prescribing information specifies discontinuation when liver enzyme elevations occur, not dose titration. There is no validated dose-dependent threshold below which tolcapone can be safely continued in the presence of transaminase elevation.
• Option C: Option C is incorrect. Switching to entacapone is a reasonable long-term plan; however, stating that no further hepatology follow-up is required once tolcapone is stopped understates the clinical responsibility. An ALT of 4.1 times normal requires hepatology review to exclude ongoing liver injury and to track normalization; automatic ALT normalization cannot be assumed without monitoring.
• Option E: Option E is incorrect. N-acetylcysteine is the antidote for acetaminophen (paracetamol) hepatotoxicity, where its mechanism of glutathione repletion is well established. It is not the established pharmacological antidote for tolcapone-induced hepatotoxicity, whose mechanism involves nitrocatechol reactive metabolites through a different pathway; administering NAC as specific antidote therapy for tolcapone hepatotoxicity is not evidence-based.

ANSWER: A

Rationale:

This question asked you to identify the correct management of dopamine agonist withdrawal syndrome and explain the rationale. Option A is correct. The clinical picture — severe non-motor symptoms of anxiety, intense drug craving, dysphoria, diaphoresis, and insomnia emerging within days of abrupt pramipexole discontinuation, disproportionate to modest motor worsening — is characteristic of dopamine agonist withdrawal syndrome (DAWS). DAWS reflects physical dependence of the mesolimbic reward system on chronic D2/D3 receptor stimulation from the dopamine agonist; abrupt removal produces a withdrawal state with features analogous to substance withdrawal. The pharmacologically correct response is reinstatement of the dopamine agonist at the previous dose to resolve the acute withdrawal state, followed by a carefully planned gradual taper that allows the mesolimbic system to adapt progressively. The impulse control disorder concern that prompted the patient's self-discontinuation is legitimate and must be addressed — but the correct response is a supervised taper with behavioral monitoring, not abrupt cessation that precipitates DAWS. The patient should be explicitly counseled never to stop pramipexole abruptly again.

• Option B: Option B is incorrect. Benzodiazepines address the anxious and adrenergic surface symptoms of DAWS but do not treat the underlying mesolimbic dopaminergic withdrawal; diazepam in an older patient carries sedation and fall risk. Permanently discontinuing pramipexole without reinstating it first is inappropriate when the patient is in full-blown withdrawal — tapering from zero does not resolve established DAWS, which requires reinstatement and then gradual reduction.
• Option C: Option C is incorrect. DAWS is not a substance use disorder in the opioid receptor sense, and buprenorphine/naloxone is an opioid medication with no established role in managing dopamine agonist withdrawal; this represents a category error in pharmacological reasoning.
• Option D: Option D is incorrect. Naltrexone is an opioid receptor antagonist and is not a pharmacological treatment for dopaminergic drug craving or DAWS; it does not address D2/D3 receptor-mediated mesolimbic dependence and would not allow the withdrawal symptoms to resolve. Uptitrating levodopa does not reliably substitute for dopamine agonist-mediated mesolimbic stimulation.
• Option E: Option E is incorrect. DAWS is a pharmacologically defined withdrawal syndrome from an identified drug, not a new-onset anxiety disorder; diagnosing it as a psychiatric condition requiring SSRI therapy misidentifies the mechanism and delays the correct pharmacological intervention of pramipexole reinstatement and supervised taper.

ANSWER: C

Rationale:

This question asked you to interpret a follow-up DAT scan showing reduced binding after initial drug-induced parkinsonism and partial recovery, and explain its clinical significance. Option C is correct. The progression from a normal DAT scan at the time of initial valproic acid-induced parkinsonism to a reduced DAT scan eighteen months after drug dose reduction — in the context of partial but incomplete motor recovery — is the clinical signature of unmasked idiopathic Parkinson's disease. In this patient's case, valproic acid exposure impaired dopaminergic neuronal function pharmacologically, producing overt parkinsonism; when the drug dose was reduced, the pharmacological stress was partially relieved and some motor improvement occurred. However, the patient was likely already in the early pre-clinical or early clinical phase of idiopathic PD — with a reduced dopaminergic reserve that had not yet crossed the clinical threshold for motor symptoms. The valproic acid exposure pushed him across that threshold prematurely. With valproic acid reduced, the residual parkinsonism and the now-reduced DAT binding reflect ongoing nigrostriatal neurodegeneration that is progressing independently of drug exposure. The putamen-predominant pattern of DAT reduction is characteristic of idiopathic PD. This patient requires ongoing management as an idiopathic PD patient, not merely as a patient recovering from drug-induced parkinsonism.

• Option A: Option A is incorrect. Valproic acid does not cause permanent mitochondrial DNA damage that produces progressive structural terminal loss as a late complication; its mitochondrial dysfunction mechanism is pharmacologically reversible with dose reduction or discontinuation, and progressive structural neuronal loss following valproic acid dose reduction is not an established sequela.
• Option B: Option B is incorrect. Dopamine agonists including pramipexole do not occupy DAT binding sites on SPECT tracers; pramipexole acts at postsynaptic D2/D3 receptors and has no affinity for the dopamine transporter. This is not a pharmacologically plausible source of false-positive DAT reduction, and a pramipexole washout would not alter the DAT scan result.
• Option D: Option D is incorrect. DAT upregulation producing a transient apparent binding dip during recovery from drug-induced parkinsonism is not an established physiological phenomenon; the reduced DAT binding observed here reflects structural terminal loss, not a transient pharmacological artifact of recovery.
• Option E: Option E is incorrect. Valproic acid does not specifically downregulate dopamine transporter protein expression on intact terminals as a distinct pharmacological mechanism; a reduced DAT scan reflects structural loss of presynaptic terminals, not transporter downregulation on intact neurons. The distinction between a transporter-expression effect and structural terminal loss is pharmacologically meaningful, and the clinical context here — progressive course despite drug dose reduction — supports structural loss.